Currently, numerous IL-17-targeted inhibitors have been approved for the treatment of autoimmune diseases such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis or for those that have advanced to phase III clinical trials. Here, IL17A is linked to ankylosing spondylitis.